selling semaglutide Drug maker sues 2 Florida firms for unapproved weight-loss medication The Semaglutide Shortage Is Ending:

How does the Precision Peptide Genetic Test personalize my GLP-1 therapy

EPS: ~$23.50 Forward P/E: ~42 (premium justified by growth) PEG Ratio: ~0.9 (attractive given growth rate) Long-Term Track Record Performance: 52-Week Range: $623.78 - $999.92 1-Year Return: +20-25% (volatile but trending up) Market Leadership: Approaching $1 trillion valuation Dividend Profile: Current Yield: ~0.6% (modest but growing) Annual Dividend: $6.00 per share Growth Rate: Consistently increasing ~15% CAGR The dividend is small now, but management prioritizes reinvestment in R&D while rewarding long-term shareholders with steady increases

Lastly, although this would be rare with standard doses, withdrawal symptoms might indicate a physical dependence or Adderall addiction

S., Drucker, D